Division of Cardiovascular Surgery, Department of Surgery, University of Pennsylvania, Philadelphia, USA.
Division of Cardiovascular Surgery, Department of Surgery, University of Pennsylvania, Philadelphia, USA.
Clinics (Sao Paulo). 2023 Apr 28;78:100205. doi: 10.1016/j.clinsp.2023.100205. eCollection 2023.
Demand for donor hearts and lungs exceeds their supply. Extended Criteria Donor (ECD) organs are used to help meet this demand, but their impact on heart-lung transplantation outcomes is poorly characterized.
The United Network for Organ Sharing was queried for data on adult heart-lung transplantation recipients (n = 447) from 2005‒2021. Recipients were stratified based on whether they received ECD hearts and/or lungs. Morbidity was analyzed using Kruskal-Wallis, chi-square, and Fisher's exact tests. Mortality was analyzed using Kaplan-Meier estimation, log-rank tests and Cox regression. Sixty-five (14.5%) patients received two ECD organs, 134 (30.0%) received only an ECD lung, and 65 (14.5%) only an ECD heart. Recipients of two ECD organs were older, more likely to have diabetes, and more likely transplanted from 2015‒2021 (p < 0.05). Groups did not differ by pre-transplant diagnosis, intensive care unit disposition, life support use, or hemodynamics. Group five-year survival rates ranged from 54.5% to 63.2% (p = 0.428). Groups did not differ by 30-day mortality, strokes, graft rejection, or hospital length of stay.
Using ECD hearts and/or lungs for heart-lung transplantation is not associated with increased mortality and is a safe strategy for increasing donor organ supply in this complex patient population.
对供体心脏和肺的需求超过了其供应。扩展标准供体 (ECD) 器官被用于帮助满足这一需求,但它们对心肺移植结果的影响尚未得到充分描述。
美国器官共享网络 (UNOS) 对 2005 年至 2021 年期间进行的成人心肺移植受者(n=447)的数据进行了查询。根据受者是否接受 ECD 心脏和/或肺,将其分层。使用 Kruskal-Wallis、卡方和 Fisher 精确检验分析发病率。使用 Kaplan-Meier 估计、对数秩检验和 Cox 回归分析死亡率。65 例(14.5%)患者接受了两个 ECD 器官,134 例(30.0%)仅接受了一个 ECD 肺,65 例(14.5%)仅接受了一个 ECD 心脏。接受两个 ECD 器官的患者年龄更大,更有可能患有糖尿病,并且更有可能在 2015 年至 2021 年期间接受移植(p<0.05)。各组在移植前诊断、重症监护病房处置、生命支持使用或血液动力学方面没有差异。5 年生存率范围为 54.5%至 63.2%(p=0.428)。各组在 30 天死亡率、中风、移植物排斥或住院时间方面没有差异。
在心肺移植中使用 ECD 心脏和/或肺与死亡率增加无关,是增加此类复杂患者群体供体器官供应的安全策略。